Neuromodulation-assisted Ego-disengagement (NEURO-EGO Stage 2)
Official title: Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study
Run by University of Wisconsin, Madison · NCT06601699 · Data updated 2026-11-12
This trial tests whether short sessions of non-invasive brain stimulation can help healthy adults new to meditation enter a meditative, ego-disengaged state more quickly and improve openness and wellbeing.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 48 (estimated) |
| Sponsor | University of Wisconsin, Madison Academic / other |
| Locations | 1 site (Madison, Wisconsin) |
| Status | Recruiting |
| Started | August 27, 2025 |
| Main results expected | July 2027 |
| Study ends | July 2028 |
| Registry record updated | June 18, 2026 |
| Trial ID | NCT06601699 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are medically healthy, English‑speaking adults age 18–80 who are meditation‑naïve, citizens or legal residents, and have no history of neurological disease, bipolar disorder, psychosis, or uncontrolled migraines.
✕Probably not a fit
People with prior or current neurological disorders, bipolar disorder or psychosis, significant head trauma, poorly controlled headaches or systemic illnesses that raise seizure risk, or those unable to travel to the site or tolerate EEG/stimulation are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Stage 2 applies the stimulation amplitude and posteromedial cortex targeting identified in earlier stages to meditation‑naïve healthy adults. Participants complete questionnaires, perform a guided meditation task called the Bell Task while wearing a high‑density EEG (hdEEG) cap, and receive one of two forms of transcranial electrical stimulation (TES or TES with temporal interference, TES‑TI). Researchers will record acute EEG responses during stimulation and follow participants longitudinally to track changes in ego‑disengagement, openness, and wellbeing. The protocol also tests whether topical anesthetic use changes the EEG response evoked by stimulation.
Why it matters
Potential benefit: If successful, this approach could offer a fast, non‑drug way to help people reach meditative states and potentially increase openness and overall wellbeing.
How similar studies have gone: Preliminary research with non‑invasive brain stimulation has shown effects on self‑related processing and cortical activity, but TES‑TI and deliberate induction of ‘ego‑disengagement’ remain experimental with limited confirmatory evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults, ages 18 to 80 of any identified gender * Medically healthy * English-speaking (able to provide consent and complete questionnaires) * Healthy adults who are meditation-naïve * Citizen or legal resident Exclusion Criteria: * Any current or past history of neurological disorders or acquired neurological disease (e.g. stroke, traumatic brain injury), including intracranial lesions * Any current or past history of bipolar disorder and/or hypomania * Any current or past history of psychosis * History of head trauma resulting in prolonged loss of consciousness; or a history of great than 3 grade I concussions * Current history of poorly controlled headaches including intractable or poorly controlled migraines * Any systemic illness or unstable medical condition that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.) * History of fainting spells of unknown or undetermined etiology that might constitute seizures * History of seizures, diagnosis of epilepsy, history of abnormal (epileptiform) EEG, or family history of treatment resistant epilepsy with the exception of a single seizure of benign etiology (e.g. febrile seizures) in the judgment of a board-certified neurologist * Possible pregnancy. All female participants of child-bearing age are required to have a pregnancy test * Any metal in the brain, skull or head * Any contraindications to MRI * Any medical devices or implants (i.e. cardiac pacemaker, medication infusion pump, cochlear implant, vagal nerve stimulator, dental implants (this includes a permanent retainer)) unless otherwise approved by the responsible MD * Substance abuse or dependence within the past six months * Any medication that may alter seizure threshold i.e., ADHD stimulants (Adderall, amphetamine); Tricyclic/atypical antidepressants (Amitriptyline, Dioxepine, Imipramine Maprotiline, Nortriptyline, Bupropion); Antipsychotics (Chlorpromazine, Clozapine), Bronchodilators (theophylline, aminophylline); Antibiotics (fluoroquinolones, imipenem, penicillin, cephalosporins, metronidazole, isoniazid); Antiviral (Valacyclovir, Ritonavir); OTC (Diphenhydramine) * Claustrophobia (a fear of small or closed places) * Back problems that would prevent lying flat for up to two hours * Having experienced a traumatic event that caused lasting distress or required treatment * Motion sickness * Any hair braid, dreadlocks, hair pieces, or extensions which cannot be taken out or adjusted to permit comfortable and comprehensive participation before the MRI scans and/or stimulation sessions * Any head coverings or headdress that participant feels uncomfortable removing for the purposes of the MRI scans and/or stimulation session
Where it's running
-
University of Wisconsin
Madison, Wisconsin, United States Recruiting
Study contacts
- Principal investigator: Melanie Boly, MD, PhD — University of Wisconsin, Madison
- Study coordinator: Simone Bruno
- Email: sbruno3@wisc.edu
- Phone: 608-209-4108
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
18F-FES PET/MRI to find hidden disease in invasive lobular breast cancer
This study tests whether adding 18F-FES PET/MRI can reveal more disease in lobular breast cancer than standard imaging alone.
-
Share or Not to Share: A Peer-Led Support Program for Caregivers of Autistic Young Adults
A group, peer-led program tests how six virtual sessions can support family caregivers of autistic young adults (ages 18–26) in navigating roles, sharing experiences, and planning for the future.
-
Decision-support tool to aid blood biomarker testing discussions in primary care
A brief tool is being tested to help primary care doctors talk with patients about blood biomarker testing for Alzheimer's disease and support shared decision-making.
-
Durvalumab plus histotripsy for intrahepatic cholangiocarcinoma
This study tests whether adding histotripsy to ongoing durvalumab helps people with advanced intrahepatic cholangiocarcinoma by boosting the immune response and checking safety.
-
Proton Therapy Treatment-Planning Software: Checking How Well RayStation and RayCare Work in Real Care
This study tests whether the RayStation 2025 and RayCare 2025 software upgrades reliably support delivering standard proton therapy to adults.
-
See if informal tick education helps kids ages 6-12
The study tests simple educational activities about ticks for children aged 6 to 12 to see how it changes their attitudes and knowledge.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.